Watch the video and download the slides.


mCSPC: Optimising patient selection and treatment

 

GU CONNECT expert, Dr Fabio Schutz provides his perspective on optimising patient selection and treatment options for metastatic castration-sensitive prostate cancer.

 

Watch the video and download the slides.

Hello, I’m Dr Fabio Schutz, I’m a Medical Oncologist at Beneficência Portuguesa hospital in São Paulo, Brazil.

 

I’m here with you today to discuss some aspects about the treatment selection in metastatic castration-sensitive prostate cancer.

 

CHAARTED Study

 

In 2014 the CHAARTED study has shown that ADT plus chemotherapy with docetaxel had a significant improvement in the overall survival of patients with metastatic castration-sensitive prostate cancer, and since then, it was suggested to give chemotherapy together with ADT for patients.

 

However, in the latest ASCO meeting there was an interesting publication, using the SEER and Optum databases presented by Dr Agarwal, that showed that since 2014 after the CHAARTED presentation, only 4% of patients had received docetaxel chemotherapy as part of their treatment and among those, only 9% of patients actually received 6 or more cycles of chemotherapy in that scenario, showing, usually that docetaxel chemotherapy is not very used in the United States, even after the CHAARTED publication in the United States, and the reason for that, perhaps can be the advances that we had with other agents such as the new androgen receptor inhibitors.

 

Androgen Receptor Inhibitors (ARIs)

 

Since 2014 several other studies with these new generation ARIs, the androgen receptor inhibitors such as abiraterone, enzalutamide and apalutamide with the studies of LATITUDE, ENZAMET, ARCHES, STAMPEDE and TITAN. They all have shown a significant improvement in overall survival in the same scenario, in the metastatic castration-sensitive prostate cancer. All those studies including the CHAARTED study with docetaxel plus ADT, they have shown similar benefits in the overall survival with about 35% reduction in the risk of death overall, with hazard ratios ranging from 0.6 to 0.7 overall.

 

STAMPEDE Trial

 

Interestingly the STAMPEDE trial conducted in the United Kingdom, they had the opportunity to compare abiraterone to docetaxel and they observed that actually abiraterone was better than docetaxel specifically in those short-term endpoints, such as failure-free survival and progression-free survival, that are mostly dependent on the PSA progression.

 

However, for the long-term endpoints such as overall survival and prostate cancer survival which are actually the most important endpoints, abiraterone and docetaxel had similar benefit – there wasn’t any statistical significance difference between docetaxel and abiraterone.

 

However, when in that trial they evaluated the quality-of-life scores comparing docetaxel and abiraterone, they showed that abiraterone had better quality-of-life scores for patients, specifically in the beginning of the treatment where patients usually receive docetaxel and after one year of follow-up the quality-of-life scores were similar between docetaxel and abiraterone.

 

So, in conclusion we can say that from an overall survival perspective there wasn’t any significant difference between docetaxel and abiraterone and perhaps, probably, compared to other androgen receptor inhibitors with indirect comparisons, however in the quality-of-life endpoints usually abiraterone was better tolerated than docetaxel which is kind of obvious because it’s not a chemotherapy.

 

TITAN and ENZAMET Trials

 

There is also some evidence, specifically from the TITAN and ENZAMET trials showing that ADT in combination with ARIs and docetaxel, so I’m meaning giving three therapies ADT plus ARIs plus docetaxel, did not show any benefit over ADT plus ARI alone. Specifically in the TITAN study was with apalutamide, and the ENZAMET trial was with enzalutamide. Therefore, so far we should not consider giving concomitant administration of apalutamide, enzalutamide or abiraterone with docetaxel.

 

ARASENS Trial

 

However, there is an important study ongoing that is evaluating exactly this situation: it’s the ARASENS study and they are comparing, ADT plus docetaxel versus ADT plus docetaxel plus darolutamide which is another important ARI that is being used. It is already approved nowadays for the non-metastatic castration-resistant prostate cancer in another scenario and they are evaluating darolutamide in the castration-sensitive scenario in this trial, the ARASENS study.

 

Thanks for watching on behalf of GU CONNECT.

Dr Fabio Schutz graduated from Parana Federal University and did his internal medicine residency at Hospital de Clinicas in Curitiba - PR, Brazil. Then, he moved to São Paulo - SP for his medical oncology clinical fellowship at Hospital Sirio Libanes. After finishing his medical oncology fellowship, he worked for a couple of years as an assistant medical oncologist in the same hospital. From 2009 to 2011, he worked as a research fellow in genitourinary (GU) oncology in the Lank Center for GU Oncology at the Dana-Farber Cancer Institute - Harvard Medical School in Boston - MA, USA. He developed several original research projects and authored many manuscripts in high-impact journals. Since mid-2011, he is working as a medical oncologist of the BP - Beneficencia Portuguesa de Sao Paulo in Sao Paulo - SP, Brazil. He is most interested and is currently conducting clinical trials in GU cancers.

Dr Fabio Schutz has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astellas, Bayer, BMS, Janssen and Ipsen 

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

podcast Podcast
Hemostasis and bleeding disorders Oncology 
Σειρά podcast για τη διαχείριση της θρόμβωσης

Αναλύσεις από καταξιωμένους ειδικούς ιατρούς. Πλοηγηθείτε στις καρτέλες για να επιλέξετε ένα επεισόδιο podcast

Experts
Prof. Dimitrios Tsakiris, Prof. Michael Nagler, Dr Lars Asmis, Prof. Jerzy Windyga
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Feb 2025

This educational programme is supported by an Independent Educational Grant from Viatris.
conference-update Conference update
Oncology 
ESMO Virtual Plenary: Final OS results from the phase III TROPION-Breast01 trial

How will the latest Dato-DXd data impact treatment strategies for HR+/HER2− mBC?

Experts
Prof. François-Clément Bidard, Dr Barbara Pistilli
  • clock 5 MIN
  • calendar Feb 2025

Educational programme supported by an Independent Educational Grant from AstraZeneca
podcast Podcast
Oncology Obstetrics and Gynecology 
Advanced or recurrent endometrial cancer: Molecular classification and treatment decisions

Understanding the role of molecular subtypes in guiding treatment selection

Experts
Prof. Xavier Matias-Guiu, Dr Jurjees Hasan
Endorsed by
Biomarker Collaborative ICAN international cancer advocacy network
  • download Downloadable
    Resources
  • clock 11 MIN
  • calendar Feb 2025

This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this Video Podcast.
podcast Podcast
Hemostasis and bleeding disorders Oncology 
Postępowanie w przypadku zakrzepicy – seria podcastów

Uznani eksperci dzielą się swoimi spostrzeżeniami. Kliknij na odpowiednią zakładkę, aby wybrać odcinek podcastu.

Experts
Prof. Dimitrios Tsakiris, Prof. Michael Nagler, Dr Lars Asmis, Prof. Jerzy Windyga
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Feb 2025

This educational programme is supported by an Independent Educational Grant from Viatris.
conference-update Conference update
Oncology 
Highlights from ASCO GI 2025

Expert insights on BRAF-mutated colorectal cancer

Experts
Dr Elena Élez
Endorsed by
DiCE
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Feb 2025

Educational programme supported by an Independent Educational Grant from Pierre Fabre Laboratories. The programme is therefore independent, the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. This content is intended for HCPs outside the UK and ROl only.
podcast Podcast

Episode

4

of 4

episode
Oncology 
HCC podcast series part 4: Intermediate HCC – the evolving role of IO

Integrating multimodal approaches with multidisciplinary care

Experts
Dr Edward Kim, Dr Nina Sanford, Dr Mark Yarchoan, Oncology Brothers (Moderators)
Endorsed by
Blue Faery plus Global Liver Institute DiCE
ELPA
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Jan 2025

Educational programme supported by an Independent Educational Grant from AstraZeneca.